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OBJECTIVE—Genetic and environmental factors modulate the
susceptibility to diabetic nephropathy, as initiating and/or
progression factors. The objective of the European Rational
Approach for the Genetics of Diabetic Complications
(EURAGEDIC) study is to identify nephropathy susceptibility
genes. We report molecular genetic studies for 127 candidate
genes for nephropathy.
RESEARCH DESIGN AND METHODS—Polymorphisms were
identiﬁed through sequencing of promoter, exon, and ﬂanking
intron gene regions and a database search. A total of 344
nonredundant SNPs and nonsynonymous variants were tested
for association with diabetic nephropathy (persistent albumin-
uria 300 mg/24 h) in a large type 1 diabetes case/control
(1,176/1,323) study from three European populations.
RESULTS—Only one SNP, rs2281999, located in the UNC13B
gene, was signiﬁcantly associated with nephropathy after correc-
tion for multiple testing. Analyses of 21 additional markers fully
characterizing the haplotypic variability of the UNC13B gene
showed consistent association of SNP rs13293564 (G/T) located
in intron 1 of the gene with nephropathy in the three populations.
The odds ratio (OR) for nephropathy associated with the TT
genotype was 1.68 (95% CI 1.29–2.19) (P  1.0  10
4). This
association was replicated in an independent population of 412
case subjects and 614 control subjects (combined OR of 1.63
[95% CI 1.30–2.05], P  2.3  10
5).
CONCLUSIONS—We identiﬁed a polymorphism in the
UNC13B gene associated with nephropathy. UNC13B mediates
apopotosis in glomerular cells in the presence of hyperglycemia,
an event occurring early in the development of nephropathy. We
propose that this polymorphism could be a marker for the
initiation of nephropathy. However, further studies are needed to
clarify the role of UNC13B in nephropathy. Diabetes 57:
2843–2850, 2008
D
iabetic nephropathy, characterized by persis-
tent albuminuria, a relentless decline in glomer-
ular ﬁltration rate and raised arterial blood
pressure, affects approximately one-third of pa-
tients with diabetes (1). Nephropathy accounts for 40% of
end-stage renal disease and is associated with high cardio-
vascular morbidity and mortality (2). Epidemiological and
familial studies suggest that genetic factors inﬂuence the
risk of diabetic nephropathy in both type 1 and type 2
diabetic patients (3–6). Despite rapid research progress,
robust predictors of this complication are still lacking.
Phenotypic characterization of nephropathy is more
accurate in patients with type 1 diabetes than in those with
type 2 diabetes, where the kidney failure may often be
caused by nondiabetic factors, mainly hypertension. Using
a concerted effort including 2,499 patients with type 1
diabetes from the Danish, Finnish, and French popula-
tions, the European Rational Approach for the Genetics of
Diabetic Complications (EURAGEDIC) consortium has
established a large study for association with diabetic
nephropathy that includes 1,176 case subjects and 1,323
control subjects (7). Single nucleotide polymorphisms
(SNPs) located in 127 candidate genes selected through
assessment of linkage studies, knowledge of metabolic
pathways, and animal models were sought for association
with nephropathy.
RESEARCH DESIGN AND METHODS
Patient populations. Three European centers, from Denmark, Finland, and
France, contributed to the case/control study, with a total of 2,499 subjects
with type 1 diabetes. Details for the recruitment of patients have previously
been presented (7) and clinical characteristics of the patients are shown in
online supplementary Table 1 (available in an online appendix at http://
dx.doi.org/10.2337/dc08-0073). Type 1 diabetes was considered present if the
age at onset of diabetes was 35 years and the time to deﬁnitive insulin
therapy 1 year. Patients in the initial phase of type 1 diabetes, that is,
duration of diabetes 5 years, were not included. Established diabetic
nephropathy (case subjects) was deﬁned by persistent albuminuria (300
mg/24 h or 200 g/min or 200 mg/l) in two out of three consecutive
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DIABETES, VOL. 57, OCTOBER 2008 2843measurements on sterile urine. Patients with clinical or laboratory suspicion
of nondiabetic renal or urinary tract disease were excluded. Absence of
diabetic nephropathy (control subjects) was deﬁned as persistent normoalbu-
minuria (urinary albumin excretion rate: 30 mg/24 h or 20 g/min or 20
mg/l) after at least 15 years of diabetes duration in patients not treated with
ACE inhibitors or angiotensin II receptor blockers.
Accordingly, for the initial study, Denmark contributed 952 patients with
type 1 diabetes including 489 case subjects and 463 control subjects for
diabetic nephropathy, Finland contributed 856 patients including 387 case
subjects and 469 control subjects, and France contributed 691 patients
including 300 case subjects and 391 control subjects, adding up to a total of
2,499 patients including 1,176 case subjects and 1,323 control subjects for
nephropathy.
Two independent datasets were used for replication, the ﬁrst one being an
additional case/control group from the FinnDiane study (8), including 412
case subjects and 614 control subjects who matched the criteria used in the
initial study. The second set consisted of 674 patients with type 1 diabetes and
microalbuminuria (urinary albumin excretion rate 30–300 mg/24 h or 20–200
g/min or 20–200 mg/l) from the Danish (n  60), Finnish (n  421), and
French (n  193) populations. Clinical characteristics for the replication
datasets are presented in online supplementary Table 2.
Molecular screening and SNP selection. The study is a systematic inves-
tigation of 127 candidate genes selected through studies of susceptibility loci
from linkage studies, metabolic pathways known to be affected in nephropa-
thy, and data from animal models. A detailed list of genes and molecular
analyses has been described elsewhere (7,9).
Single nucleotide polymorphisms (SNPs) in the genes selected for the
study were identiﬁed through database searches and by direct SNP discovery.
A total of 119 genes were screened by sequencing all exons, ﬂanking intron
sequences, 5 and 3 untranslated regions, and promoter regions in at least 32
DNA samples. The sample consisted of healthy French Caucasian subjects
from the Epidemiological Study on the Genetics and Environment of Asthma
(EGEA) (10). The sample size allowed us to detect SNPs with a minor allele
frequency (MAF) of at least 5% with a probability of 96%. For 33 genes that
were not initially included in the French National Genotyping Centre (CNG)
resequencing effort of 15,000 human genes (http://www.cng.fr/en/teams/
geneident/index.html), the screening was performed in 64 additional DNA
samples from patients with type 1 diabetes. These included 24, 20, and 20
patients from Denmark, Finland, and France, respectively, half of them (n 
32) with nephropathy and the other half (n  32) without. For sequencing,
DNA samples of two individuals from the same population and with the same
phenotype were pooled together. Accordingly, the screening was performed in
16 DNA pools for 86 genes and in 48 (16  32) DNA pools for 33 genes.
For each gene, primers were deﬁned for PCR ampliﬁcation of the exon and
promoter regions. PCR was performed in a 15-l reaction mixture containing
25 ng pooled genomic DNA. Primer sequences are available from the authors
on request. Sequencing reactions were performed according to the dye
terminator method using an ABI PRISM 3700 DNA Analyzer (Applied Biosys-
tems, Foster City, CA). Alignment of experimental results, SNP detection, and
genotype calling were performed using the Genalys software (11) that allows
for genotype calls obtained from pooled DNA.
For each gene, the haplotype structure and frequencies were determined
from the genotypic data obtained from the control group and population
groups using the expectation maximization (EM) algorithm (12). A total of 350
variants were selected to account for all estimated haplotypes with frequen-
cies 5%. These tagSNPs represented a median genetic variation (haplotype
diversity) by gene of 87% (range 64–100%). All were retained for further
genotyping in the case/control study. In addition, all nonsynonymous variants
that were detected in at least one diseased population were systematically
investigated (n  19).
For two genes (RELA, TGFBR1) for which no polymorphisms were
identiﬁed, SNPs were selected using the SNPBrowser software v.2 (Applera
Corporation). For eight additional genes (CCR5, CNDP1, HNF4A, LTA, PON2,
GCGR, INPPL1, PLA2G7), polymorphisms were selected according to
reported associations with phenotypes relevant for diabetic nephropathy
(13–20). We also examined 94 SNP markers (genomic control markers) in
nongenic regions spaced throughout the genome to control for possible
stratiﬁcation within each population (21,22).
A total of 21 additional SNPs in the UNC13B gene (GeneID#10497; full
name unc-13 homolog B [C. elegans]) were genotyped after the initial positive
association results from the ﬁrst step. These additional SNPs were selected
from the Hapmap project (http://www.hapmap.org) so that 95% of the
UNC13B haplotypic variability was characterized.
Genotyping. Genomic DNA was isolated from human leukocytes using
standard methods. SNP genotyping was performed at the French National
Genotyping Center (CNG) using automated high-throughput methods includ-
ing TaqMan, Ampliﬂuor, MALDI-MS, and SNPlex methods. All liquid handling
was performed robotically in 384-well plates with a BasePlate Robot (The
Automation Partnership, Royston, U.K). For SNP genotyping by mass spec-
trometry, the GOOD assay was applied as previously described (23). TaqMan
(assay-by-design) was carried out in a 5-l volume according to the manufac-
turer’s recommendations, with probes and mastermix from Applied Biosys-
tems. For Ampliﬂuor, primers were designed using “AssayArchitect” (http://
www.assayarchitect.com). Primer sequences and conditions are available on
request. End point ﬂuorescence was detected for TaqMan and Ampliﬂuor
assays using an ABI7900HT reader (Applied Biosystems, Courtaboeuf,
France), and genotypes were assigned with SDS 2.1 software. Genotyping with
the SNPlex platform was performed according to the manufacturer’s recom-
mendations (Applied Biosystems, Courtaboeuf, France).
The genotyping success rate was 85% for all markers (90% for 3% of the
markers, between 90 and 95% for 17%, and 95% for 80% of the markers), and
among 192 replicate samples genotyped blindly, no genotype differences were
found. Hardy-Weinberg equilibrium was checked in case subjects and control
subjects in all populations, and markers showing deviation from Hardy-
Weinberg equilibrium at the 0.001 signiﬁcance level were not considered in the
case/control comparison.
Statistical analysis. Allele frequencies were estimated by gene counting, and
deviation from Hardy-Weinberg equilibrium was tested by use of a 	
2 with 1
d.f. Difference in allele frequencies between case subjects and control subjects
were tested by a 	
2 test with 1 d.f. separately in each population, and
associated P values were combined across populations using Fisher’s method
(24) to produce an overall test of signiﬁcance. Adjustment for multiple testing
was carried out by correcting for the effective number of independent tests
(25) to take into account the linkage disequilibrium (LD) between SNPs.
Logistic regression analyses were performed to estimate genetic ORs, ad-
justed for age, sex, smoking, diabetes duration, and A1C. LD matrices were
obtained using Haploview software (26), and haplotype association analyses
were carried out using THESIAS software (27). Homogeneity of ORs across
populations was investigated using the Mantel-Haenszel statistic (28).
Expression studies
Cell culture. Cell lines HepG2, MDCK I and II, MCF7, Cos7, HeLa, EAhy-926,
SaOs-2, U2Os, SHSY5Y, and rat smooth muscle cells (rSMC) were maintained
in Dulbecco’s modiﬁed Eagle’s medium (Sigma, Geissendorf, Germany) with
10% conditioned fetal calf serum (PAA, Co ¨lbe, Germany), penicillin (100
units/ml), streptomycin (100 ng/ml), and L-glutamin (2 mmol  l
1  ml
1).
HEK293T cells received iron-supplemented fetal calf serum (Cell Concepts,
Umkirch, Germany). Suspension cell lines THP1, U937, K562, HL60, and
RAW264.7 were maintained in RPMI-1640 medium (Sigma) with the same
additions plus 1  minimal essential medium (MEM) minimal amino acids
(PAA). Differentiation of THP-1 monocytes into macrophages induced by
stimulation with 10
8 mol/l phorbol 12-myristate 13-acetate (PMA) and
differentiation of SaOs-2 osteosarcoma cells was induced by stimulation with
100 mmol/l glycerol-1-phosphate and 10 mmol/l ascorbic acid.
Isolation of total RNA and generation of cDNA. Total RNA from cells was
isolated from 10
6 cells each with the RNeasy Mini Kit (Qiagen, Hilden,
Germany) following the manufacturer’s protocol. RNA from human brain was
extracted from the left frontal cortex of a 75-year-old male patient 24 h
postmortem, and testis RNA was isolated 1 h after surgical operation from a
62-year-old patient who underwent orchidectomy for prostate cancer as
described (29). RNA yield was controlled by TBE/agarose gel electrophoresis
and adjusted nanophotometrically. For ﬁrst-strand cDNA synthesis, 5 g total
RNA was used (Fermentas, St. Leon-Rot, Germany). Efﬁciency was routinely
controlled by diagnostic PCR for ribosomal protein RP27. Podocyte cDNA
was generated from an immortalized human podocyte cell line (30).
Diagnostic PCR. Exon-spanning primers for nested diagnostic PCR were
designed from UNC13B sequence NM_006377 (sense primers S1: GTGCAC
CACTCCTCATAACTT; S2: CAACCTACTGCTATGAGTGT; antisense primers
A1: TGTGCAAGTCA GCAAAACTAAG, A2: AAGCCAAGGACAAAACAG
GATC). PCR was conducted with GoTaqDNA-Polymerase (Promega) and 35
cycles of ampliﬁcation. Integrity of the cDNA was controlled by diagnostic
PCR for ribosomal protein 27 (rp27; sense primer: 5-CCAGGATAAGGAAGG
AATTCCTCCTG-3, antisense primer: 5-CCAGCACCACATTCATCAGAAGG-
3, not shown).
In silico analyses. For the prediction of putative transcription factor binding
sites, a sequence of 25 bases to either side of the SNP was submitted for each
SNP individually to a net-based search tool (Alibaba2.1, Transfac7.0; http://
www.gene-regulation.com). Settings for core and pair similarities, matrix
conservation, and factor class levels were adjusted according to factors
predicted.
Five polymorphisms, rs10081672, rs10972356, rs13288912, rs12377498, and
rs10972333, were in complete association with rs13293564 located in intron 1
of the UNC13B gene associated with nephropathy. They were detected on the
NCBI B35 (http://www.ncbi.nlm.nih.gov) at the respective nucleotide posi-
tions 35145908, 35143435, 35143123, 35140841, and 35126146, with the beginning
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site was conﬁrmed in all reference sequences in the University of California,
Santa Cruz genome browser, with no indication of alternative upstream exons or
presence of alternative promoters. Hence, the variants rs10081672, rs10972356,
rs13288912, rs12377498, and rs10972333 are located, respectively, 6,081, 8,554,
8,866, 11,148, and 25,843 bp upstream of the transcription start site of the
human UNC13B gene. Sequence homology scans and chromosomal neighbor-
hood analyses were performed using the University of California, Santa Cruz
genome browser (http://genome.ucsc.edu) covering chromosomal region
9:35,101,909–35,160,332. Special emphasis was put on placental mammal con-
served elements in a 28-way multiz alignment. Results were cross-checked using
rVista 2.0 software (http://rvista.dcode.org). There was no noticeable sequence
conservation this far upstream of UNC13B exon 1 in either species.
RESULTS
SNP discovery, selection, and genotyping. A total of
119 genes were resequenced and 1,833 sequence variants
were detected, including 1,673 SNPs and 160 insertion/
deletion polymorphisms. A total of 773 (42.2%) of these
variants were not present in the dbSNP (build 126) and
therefore represent novel polymorphisms. All data have
been cataloged in the dbSNP database and are available
online at http://genecanvas.ecgene.net. They were located
in the 5-ﬂanking region (n  53), 5UT (n  31), intron (n
 1,166), nonsynonymous coding (n  139), slice site (n
1), 3UT (n  221), and the 3-ﬂanking region (n  40).
The proportion of SNPs detected in exons was not differ-
ent between the 773 newly discovered polymorphisms and
the 1,060 variants in dbSNP build 126 (32.4 vs. 30.3%, 	
2
test: P  0.35). As expected, newly discovered SNPs were
mainly rare, 66.1% with MAF 5% compared with 12.3% of
SNPs in dbSNP (P  10
4). The same held true for
insertions/deletions (17.2% new vs. 2.5% in dbSNP, P 
10
4).
A total of 532 haplotypes with a frequency 5% in at
least one population were determined. For these 119
genes, a total of 369 polymorphisms, including haplotype-
tagging SNPs and nonsynonymous variants, were selected
for genotyping. For two genes with no variant identiﬁed
through resequencing (RELA, TGFBR1), four SNPs were
selected with SNPbrowser. In addition, 15 SNPs were
selected in eight genes from previously reported associa-
tions with phenotypes relevant for diabetic nephropathy.
We were not able to obtain data for 28 markers due to the
impossibility of obtaining a genotyping assay, and 16
markers were excluded because they showed signiﬁcant
deviation from the Hardy-Weinberg equilibrium in case
subjects and control subjects from the three populations.
Association studies. A total of 344 SNPs were investi-
gated for association with nephropathy in the EURAGE-
DIC study. Allele frequencies in case and control groups
from three populations are shown in supplementary Table
3 (in the online appendix). Nominally signiﬁcant associa-
tion across the three populations (P  0.05) was observed
for 33 SNPs of 344, with P values ranging from P  1.79 
10
5 to P  0.050 (supplementary Table 3). Of the 15
polymorphisms in the eight genes selected from the liter-
ature, only one, rs1799987, located in the CCR5 gene,
showed nominal signiﬁcant association across the three
populations (P  0.025). However, this association did not
remain signiﬁcant after correction for multiple testing. For
the 119 remaining genes, the number of independent tests
was estimated to be Neff  317, with a corresponding
signiﬁcance threshold of P  1.58  10
4 (P  0.05/317).
Only one SNP, rs2281999, located in UNC13B, remained
signiﬁcantly associated with nephropathy (P  1.79 
10
5) after correction. This association was mainly ob-
served in the Finnish sample, with a trend remaining in the
Danish but not in the French samples (Table 1 and
supplementary Table 3). Another UNC13B SNP (rs661712)
showed nominal evidence for association with nephropa-
thy (P  4  10
4) but did not remain signiﬁcant after
correction for multiple testing. The association for the 94
genomic control markers was compatible with expecta-
tions under the null hypothesis of no association, indicat-
ing that stratiﬁcation within one or more of the
populations is an unlikely source of positive association
results. Furthermore, correction of the association for the
two signiﬁcant eigenvectors identiﬁed by performing prin-
cipal components analysis (using Eigenstrat) on the
genomic control markers had no effect on the results.
Our initial sequencing of the 39 exons of UNC13B has
identiﬁed a total of 13 SNPs that could be tagged by four
SNPs. These four SNPs, together with a nonsynonymous
variant located in exon 28 (R1124Q), were genotyped in
the whole EURAGEDIC sample. However, analysis of the
available HapMap data revealed that these four SNPs were
not sufﬁcient to correctly characterize the haplotypic
variability of the gene, which spans over 
240 kb on
chromosome 9p12-p11. Therefore, 21 additional tagging
SNPs spanning the whole gene were further genotyped to
clarify the observed association of UNC13B SNPs with
nephropathy (Fig. 1). The results of association analyses
of all UNC13B SNPs (apart from two rare variants shown
in supplementary Table 3) with nephropathy are summa-
rized in Table 1. While most of the SNPs were associated
with nephropathy in the whole study, none showed signif-
icant allelic association in the three populations, and only
one, rs13293564, showed nominal allelic association in two
populations: Denmark and Finland. In these two popula-
tions, homozygous carriers of the T allele were more
frequent in case subjects than in control subjects (0.18 vs.
0.12 and 0.25 vs. 0.17, respectively) and were then at higher
risk of nephropathy (OR 1.60 [1.10–2.32], P  0.013; OR
1.57 [1.11–2.22], P  0.011, respectively) (supplementary
Table 4). Interestingly, French homozygous carriers of this
allele also tended to be more frequent in case subjects
than in control subjects (0.18 vs. 0.15), but the association
failed to reach nominal signiﬁcance (OR 1.26 [0.83–1.92],
P  0.278). These three ORs were not statistically different
from each other (P  0.663) and were therefore combined,
leading to an increased risk of nephropathy associated
with the TT genotype of OR 1.49 (95% CI 1.20–1.85) (P 
0.0003). Further adjustment for smoking and A1C did not
modify these associations (supplementary Table 4).
One feature of the French patients with diabetes is that
76% of them had proliferative retinopathy, whereas this
percentage was 49 and 58 in Denmark and Finland,
respectively (7, supplementary Table 1). Further adjust-
ment for retinopathy status strengthened the observed
association, in particular in France, where the OR associ-
ated with the TT genotype was then similar to that
observed in Denmark (Fig. 2), leading to a common OR for
nephropathy associated with the TT genotype of 1.68 (95%
CI 1.29–2.19) (P  0.0001). This was explained by the
slightly more pronounced difference in TT genotype fre-
quencies between case subjects and control subjects ob-
served in patients without proliferative retinopathy (0.25
vs. 0.15) than in patients with proliferative retinopathy
(0.19 vs. 0.13) (supplementary Table 5). However, no
heterogeneity was detected according to the retinopathy
status (P  0.48).
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rs2281999 and rs13293564 SNPs showed that the difference
in the genotype distribution between case subjects and
control subjects mainly came from the rs13293564-TT
genotype, suggesting that the initial association observed
between the rs228199 and nephropathy was due to its LD
with the rs13293564. All further LD, multilocus, and hap-
lotype analyses converge to a unique recessive effect of the
rs13293564 polymorphism (supplementary Tables 6–8,
supplementary Fig. 1), an effect that occurs homoge-
neously in men and women (data not shown) and across
the three EURAGEDIC populations.
The rs13293564 SNP was further investigated in an
independent Finnish sample from the FinnDiane study (8)
including 412 case subjects with nephropathy and 614
control subjects. In this population, the TT genotype was
also associated with an increased risk of nephropathy (OR
1.45 [1.06–1.98]) (P  0.020) that was hardly modiﬁed by
further adjustment for smoking, A1C, and proliferative
retinopathy (OR 1.51 [0.97–2.36]; P  0.070). Finally, in the
combined sample from the EURAGEDIC and FinnDiane
studies, the adjusted OR for nephropathy associated with
the TT genotype was 1.63 (95% CI 1.30–2.05) (P  2.3 
10
5) (Fig. 2).
The rs13293564 SNP was further investigated in 674
patients with type 1 diabetes and microalbuminuria from
the three populations. The frequency of the TT genotype in
patients with microalbuminuria was signiﬁcantly higher
than the frequency of this genotype in patients with
normoalbuminuria (0.22 vs. 0.15, P  10
4) (supplemen-
tary Table 9). The frequency of the TT genotype was
similar, whatever the stage of diabetic nephropathy, incip-
ient nephropathy (microalbuminuria) (0.22), macroalbu-
minuria (0.21), or end-stage renal disease (ESRD) (0.23)
(supplementary Table 9).
Assuming a minor allele frequency of 0.39 at the
rs13293564 locus in patients with type 1 diabetes and an
increased risk of 1.6 in homozygous carriers of the T allele,
the population attributable risk for rs13293564 would be
8.3%.
Expression studies. A diagnostic PCR for UNC13B tran-
scripts in various cell lines and tissues (supplementary
Fig. 2) was performed. The strongest expression of
UNC13B was detectable in human tissues from brain,
testis, and podocytes, as well as the human immortalized
podocyte cell line SHSy. Kidney cell lines COS7, and to a
minor extent MDCK I and II, express UNC13B, but not
embryonic kidney cell line HEK293T. Osteosarcoma cell
lines (SaOs2, U2Os), liver (HepG2), and breast cancer
(MCF7) show noticeable expression, whereas in mono-
cytic cell lines, either differentiated or not, expression is
strictly cell-line dependent. Choriocarcinoma cells HeLa
do not express UNC13B.
In silico analyses. There was no feature to suggest that
rs13293564 located in intron 1 of the UNC13B is the
functional variant. Analyses of the ﬁve polymorphisms in
35130K 35180K 35230K 35280K 35330K 35380K
Chr9
FIG. 1. Schematic representation of the UNC13B gene. The structure of UNC13B gene on chromosome 9 is presented with the respective positions
of the 39 exons and of the 24 SNPs genotyped (rsID are given in Table 1), as well as the HapMap haplotype blocks (in D). Arrows at both ends:
SNPs selected through sequencing; single arrow: haplotype tagging SNPs selected from Hapmap; arrow with bullet: position of rs13293564, the
SNP associated with nephropathy; dashed arrow with bullet: SNPs in complete association with rs13293564 (not typed).
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DIABETES, VOL. 57, OCTOBER 2008 2847complete association with rs13293564 (rs10081672,
rs10972356, rs13288912, rs12377498, and rs10972333) lo-
cated in the putative promoter region showed that the
rs10081672 and rs10972333 SNPs, located respectively
at positions 6081 and 25843 bp upstream of the
transcription start site of the human UNC13B gene,
affect potential Sp1 and upstream stimulating factor
binding sites, respectively.
DISCUSSION
We have shown for the ﬁrst time that a common variation
in the UNC13B gene was reproducibly associated with
nephropathy. A recent study that assessed 115 candidate
genes for nephropathy in 82 trios did not ﬁnd signiﬁcant
results for any of the six UNC13B markers analyzed (31).
This might be explained by the insufﬁcient number of
markers studied and a study of limited power.
The rs13293564 lies within the ﬁrst intron of the
UNC13B gene and is in strong LD with many other SNPs
all along the gene (see supplementary data and HapMap
data). However, it is in complete association with only ﬁve
SNPs (rs10081672, rs10972356, rs13288912, rs12377498,
and rs10972333) located in the putative promoter region.
While there is no feature to suggest that rs13293564 is the
functional variant, rs10081672 and rs10972333, located
respectively at positions 6081 and 25843 bp upstream
of the transcription start site of the human UNC13B gene,
affect potential Sp1 and USF binding sites, respectively,
suggesting that those SNPs could be the functional vari-
ants. It is possible that regulatory elements are located this
far upstream of the proximal regulatory regions within the
core promoter. Functional molecular analyses are needed
to clarify their impact. It should also be stressed that an
expressed repetitive element NM_001039797 of 3.032 kbp
is located within UNC13B intron 1, 20 kb downstream of
rs13293564, the function of which is unknown, and strong
LD spans over this region. This opens up the possibility
that genetic variation affects a regulatory element for
UNC13B within the intronic region. Such mechanisms
have recently been shown to be involved in susceptibility
to different diseases (32–34).
The human UNC13B gene product (also called
Hmunc13) has been cloned from the human kidney library
(35) and is homologous to rat munc13 proteins, which are
members of the protein kinase C (PKC) superfamily that
lack a kinase domain. Human UNC13B has one C1 diacyl-
glycerol (DAG) and three C2 (Ca
2) binding domains. It is
both upregulated and activated in the presence of hyper-
glycemia in renal cortical tubular cells and in glomerular
mesangial cells (36). Using RT-PCR to further assess the
expression of UNC13B in human tissues, we found that
UNC13B was also highly expressed in podocytes (supple-
mental Fig. 2). It has been shown that DAG activation of
UNC13B-expressing cells induces apoptosis. As hypergly-
cemia increases intracellular DAG levels and is associated
with apoptosis in various tissues, including human kidney,
it is plausible that UNC13B plays a role in mediating renal
complications of diabetes (36). Apoptosis of glomerular
cells occurs quite early in the natural history of diabetic
nephropathy, and it is now recognized that it could be an
inciting event rather than a late consequence caused by
increasing proteinuria (37–41). Interestingly, TT carriers
of UNC13B_rs13293564 tended to be at slightly higher risk
of nephropathy if they had not yet developed proliferative
retinopathy, a clinical control for longstanding diabetes,
emphasizing the role of UNC13B at the early stage of the
disease. This is further strengthened by our observation
that the frequency of the UNC13B_rs13293564 TT geno-
type in patients with incipient diabetic nephropathy, an
early stage of the renal complication characterized by the
presence of microalbuminuria, was signiﬁcantly higher
than the frequency of this genotype in control subjects.
The similar distribution of the UNC13B_rs13293564 poly-
morphism genotype in three groups of patients with dif-
ferent stages of diabetic nephropathy also suggests that
this polymorphism is implicated in the initiation rather
than in the progression of the disease to more severe
stages. However, because of the cross-sectional design of
this study, we cannot exclude a survival bias in the ESRD
group that would artiﬁcially modify the allele frequency
patterns of susceptibility genes in this group.
The molecular analyses of the other 118 candidate genes
identiﬁed no further variant associated with nephropathy.
However, the SNPs genotyped in this study do not tag the
haplotype architecture of these loci; rather, they tag a
subset of the haplotypes across these genes based on the
SNPs identiﬁed around exons, ﬂanking intronic sequence,
TABLE 2
Genotype distribution derived from rs2281999 and rs13293564 according to diabetic nephropathy status in the whole EURAGEDIC
study
Control subjects rs13293564 Case subjects rs13293564
rs2281999 GG (36%) GT (50%) TT (14%) rs2281999 GG (32%) GT (48%) TT (20%)
CC (43%) 112 (9%) 261 (22%) 147 (12%) CC (50%) 94 (9%) 241 (22%) 201 (19%)
CT (46%) 219 (18%) 323 (27%) 17 (2%) CT (42%) 177 (17%) 263 (24%) 11 (1%)
TT (11%) 115 (9%) 15 (1%) 1 TT (8%) 81 (7%) 10 (1%) 0
0 0.5 1 1.5 2 2.5 3 3.5
Denmark   459 / 484
France       370 / 291 
Finland     467 / 386
Whole EURAGEDIC 1296 / 1161
FinnDiane replication   614 / 412
Whole samples     1910 / 1573 OR = 1.63 [1.30 – 2.05] p = 2.3 10-5
OR = 1.48 [1.24 – 1.76] p = 1.8 10-5
Odds Ratio for DN associated with the TT genotype at the
rs13293564 polymorphism
FIG. 2. ORs for diabetic nephropathy associated with the TT genotype
at the rs13293564 polymorphism. Number of control subjects/number
of case subjects is shown. , OR adjusted for age and sex; f,O R
adjusted for age, sex, smoking, A1C, and proliferative retinopathy.
UNC13B GENE AND NEPHROPATHY
2848 DIABETES, VOL. 57, OCTOBER 2008untranslated regions, and promoters. To fully characterize
the haplotypic variability of these genes, as would tagging
SNPs selected from the Hapmap project, the genotyping of

1,300 SNPs would be required, while 344 have been
typed in this study. Therefore, we cannot exclude that
these candidate genes contribute to the development of
diabetic nephropathy.
Our strategy, based on the genetic assessment of many
candidate genes in a large case/control study for diabetic
nephropathy, including material from three different Eu-
ropean populations, provided evidence of replicated asso-
ciation between UNC13B and nephropathy and allowed us
to establish for the ﬁrst time the involvement of UNC13B
variants in nephropathy. To assess whether or not these
variants are clinically relevant to predict the initiation of
nephropathy or the progression to more advanced stages
of nephropathy will require further investigation in co-
horts of patients with follow-up data.
URLs. HapMap: http://www.hapmap.org; UCSC genome
browser:http://genome.ucsc.edu;NCBI:http://www.ncbi.nlm.
nih.gov; Alibaba2.1, Transfac7.0: http://www.gene-regulation.
com; and http://genecanvas.ecgene.net: genotypic data for all
markers, phenotypic covariates from Danish and French
samples, and a table describing all variations identiﬁed in the
EURAGEDIC study.
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